Several molecular mechanisms are known to enhance the progression of prostate cancer to CRPC, including androgen receptor (AR) gene mutation, amplification, or overexpression [2–4], post-translational modifications, co-activator, and co-repressor modifications [5], alternative pathways bypassing AR signaling [6], and ligand-independent activation of AR [7]. Here, AR is linked to prostate carcinoma.